摘要
Diffuse large B-cell lymphoma （DEBCL） is the most common lymphoid neoplasms in adults. Through the decades, rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine （R-CHOP） therapy has dramatically improved the clinical outcome due to the introduction of rituximab. Even so, still about 30-40% of patients ultimately relapse or progress, which become difficult to manage. A study has shown that patients with primary refractory DLBCL or early relapse after rituximab-containing therapy have a very poor prognosis, which makes the introduction of novel drugs to DEBCL regimen definitely an urge demand.
Diffuse large B-cell lymphoma （DEBCL） is the most common lymphoid neoplasms in adults. Through the decades, rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine （R-CHOP） therapy has dramatically improved the clinical outcome due to the introduction of rituximab. Even so, still about 30-40% of patients ultimately relapse or progress, which become difficult to manage. A study has shown that patients with primary refractory DLBCL or early relapse after rituximab-containing therapy have a very poor prognosis, which makes the introduction of novel drugs to DEBCL regimen definitely an urge demand.
